IP Verse

Celgene Corporation opposition analysis

COMPANY ANALYSIS

Latest patents of Celgene Corporation opposed by its competitors

Patent:
EP3370729
Grant Date:
Sep 27, 2023
Title:
Methods For The Identification, Evaluation And Treatment Of Patients Having Multiple Myeloma
Oppositions:
1
Patent:
EP2651400
Grant Date:
Jan 18, 2023
Title:
Controlled Release Oral Dosage Forms Of Poorly Soluble Drugs And Uses Thereof
Oppositions:
1
Patent:
EP3880802
Grant Date:
Sep 7, 2022
Title:
Improved T Cell Manufacturing Process
Oppositions:
1
Patent:
EP3782611
Grant Date:
Jul 6, 2022
Title:
Oral Formulations Of Cytidine Analogs And Methods Of Use Thereof
Oppositions:
5
Patent:
EP3692983
Grant Date:
Aug 11, 2021
Title:
Oral Formulations Of Cytidine Analogs And Methods Of Use Thereof
Oppositions:
6
Patent:
EP3320902
Grant Date:
Feb 17, 2021
Title:
Methods For Treating Diseases Using Isoindoline Compounds
Oppositions:
1
Patent:
EP2797581
Grant Date:
May 6, 2020
Title:
Formulations Of (+)-2-[1-(3-Ethoxy-4-Methoxy-Phenyl)-2-Methanesulfonyl-Ethyl]-4-Acetyl Aminoisoindoline-1,3-Dione
Oppositions:
3
Patent:
EP2695609
Grant Date:
Dec 11, 2019
Title:
Oral Formulations Of Cytidine Analogs And Methods Of Use Thereof
Oppositions:
4
Patent:
EP2687213
Grant Date:
Jul 17, 2019
Title:
Solid Forms Comprising (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione, Compositions Thereof, And Uses Thereof
Oppositions:
1
Patent:
EP2223688
Grant Date:
May 29, 2019
Title:
(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof
Oppositions:
5

Competitors of Celgene Corporation

TEVA PHARMACEUTICAL INDUSTRIES LTD.

GENERICS (UK) LTD

HOFFMANN EITLE PATENT- UND RECHTSANWALTE PARTNERSCHAFTSGESELLSCHAFT MBB

Want to track Celgene Corporation?

Feel free to send us a message here and we will get back to you